A Phase 2 interventional study of Group 1: AR882 Alone and in Combination with Febuxostat (FBX) and Group 2: AR882 Alone and in Combination with Allopurinol (ALLO) in Gout Patients, sponsored by Arthrosi Therapeutics. Completed at 1 site in New Zealand. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-11-19.
Sponsored by Arthrosi Therapeutics (part of Swedish Orphan Biovitrum) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study is designed to evaluate the PK/PD, safety and tolerability of AR882 alone or in combination with febuxostat or allopurinol when administered to gout patients.
240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.
This study's enrollment of 30 is below the median of 68 across 193 interventional studies indexed under Hyperuricemia.
Browse Hyperuricemia studies →Arthrosi Therapeutics is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Group 1: AR882 Alone and in Combination with Febuxostat (FBX)
Drug: Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)
AR882 + Febuxostat, AR882 alone, Febuxostat alone
Also known as: Febuxostat (Adenuric®, Uloric®)
AR882 + Allopurinol, AR882 alone, Allopurinol alone
Also known as: Allopurinol (Allosig®, Progout®, Zyloprim®)
PD profile of AR882 administered alone or in combination with febuxostat
Profile from serum uric acid concentration over time
Time frame: 22 Days
PD profile of AR882 administered alone or in combination with allopurinol
Profile from serum uric acid concentration over time.
Time frame: 22 Days
Serum uric acid (sUA) response rate
sUA response rate to achieve sUA \<6, \<5, \<4, and \<3 mg/dL
Time frame: 22 Days
Area under the curve (AUC) for plasma AR882
Profile from plasma in terms of AUC for AR882
Time frame: 22 Days
Time to maximum plasma concentration (Tmax) for AR882
Profile from plasma in terms of Tmax for AR882
Time frame: 22 Days
Maximum plasma concentration (Cmax) for AR882
Profile from plasma in terms of Cmax for AR882
Time frame: 22 Days
Apparent terminal half-life (t1/2) for AR882
Profile from plasma in terms of t1/2 for AR882
Time frame: 22 Days
Amount excreted (Ae) into urine for AR882
Profile from urine in terms of Ae for AR882
Time frame: 22 Days
Renal clearance (CLr) for AR882
Profile from urine in terms of CLr for AR882
Time frame: 22 Days
AUC for plasma for febuxostat
Profile from plasma in terms of AUC for febuxostat
Time frame: 22 Days
Tmax for febuxostat
Profile from plasma in terms of Tmax for febuxostat
Time frame: 22 Days
Cmax for febuxostat
Profile from plasma in terms of Cmax for febuxostat
Time frame: 22 Days
t1/2 for febuxostat
Profile from plasma in terms of t1/2 for febuxostat
Time frame: 22 Days
AUC for plasma allopurinol/oxypurinol
Profile from plasma in terms of AUC for allopurinol/oxypurinol
Time frame: 22 Days
Tmax for allopurinol/oxypurinol
Profile from plasma in terms of Tmax for allopurinol/oxypurinol
Time frame: 22 Days
Cmax for allopurinol/oxypurinol
Profile from plasma in terms of Cmax for allopurinol/oxypurinol
Time frame: 22 Days
t1/2 for for allopurinol/oxypurinol
Profile from plasma in terms of t1/2 for allopurinol/oxypurinol
Time frame: 22 Days
Ae in urine for allopurinol/oxypurinol
Profile from urine in terms of Ae for allopurinol/oxypurinol
Time frame: 22 Days
CLr for allopurinol/oxypurinol
Profile from urine in terms of CLr for allopurinol/oxypurinol
Time frame: 22 Days
AUC for plasma for colchicine
Profile from plasma in terms of AUC for colchicine
Time frame: 22 Days
Tmax for colchicine
Profile from plasma in terms of Tmax for colchicine
Time frame: 22 Days
Cmax for colchicine
Profile from plasma in terms of Cmax for colchicine
Time frame: 22 Days
t1/2 for for colchicine
Profile from plasma in terms of t1/2 for colchicine
Time frame: 22 Days
Incidence of Adverse Events, changes in laboratory, electrocardiogram, and vital signs
Time frame: 28 Days
Ran from Feb 2020 to primary completion in Sep 2020, 7 months.
Of 24 phase 2 interventional studies under Hyperuricemia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.